文献速递腹部技术与安全US

隐匿性乙型肝炎感染者肝细胞癌的超声造影诊断算法

Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B.
PubMed 文献 · Abdom Radiol (NY) · 2021-11-20

回顾性纳入251例隐匿性乙型肝炎病毒(HBV)感染患者的251个新发局灶性肝病变,评估超声造影(CEUS)肝脏影像报告和数据系统(LI-RADS)2017版对肝细胞癌(HCC)的诊断效能,并提出一种诊断算法:对于甲胎蛋白(AFP)>20 μg/L的患者,LR-5结节诊断为明确的HCC;该算法可使12.2%(30/246)的结节通过CEUS确诊HCC而无需活检。

要点

  • 在隐匿性HBV感染患者中,CEUS LR-5诊断HCC的敏感度58.9%、特异度88.8%、准确率78.1%。
  • 90个HCC中仅53个(53.5%)被归为LR-5,2个(2.0%)为LR-4,35个(35.4%)为LR-M。
  • 作者提出的算法(AFP>20 μg/L者LR-5即诊断HCC)敏感度62.2%、特异度71.4%、准确率63.5%。

核心结论

  • 在隐匿性HBV感染患者中诊断HCC具有挑战性;但以LR-5作为无创诊断标准用于AFP>20 μg/L的隐匿性HBV感染患者时,可通过CEUS确诊HCC而无需活检。

研究设计与样本

  • 回顾性纳入251例隐匿性HBV感染患者的251个新发局灶性肝病变,每个结节按CEUS LI-RADS 2017版评估,并对AFP>20 μg/L与否进行亚组分析。

关键影像表现/征象

  • 90个HCC中,2个(2.0%)归为LR-4,53个(53.5%)归为LR-5,35个(35.4%)归为LR-M。
  • AFP升高的HCC占50.6%(45/89)。

诊断标准与关键数值

  • CEUS LR-5诊断HCC的敏感度58.9%、特异度88.8%、准确率78.1%、阳性预测值74.6%、阴性预测值79.4%。
  • 作者提出的算法(AFP>20 μg/L者LR-5结节诊断为明确HCC)敏感度62.2%、特异度71.4%、准确率63.5%、阳性预测值93.3%、阴性预测值22.7%。
  • 采用该算法,12.2%(30/246)的结节可通过CEUS确诊HCC而无需活检。

临床应用与阅片要点

  • 对隐匿性HBV感染患者的新发局灶性肝病变,可按CEUS LI-RADS 2017版评估并归类为LR-4、LR-5或LR-M。
  • 作者提出:对AFP>20 μg/L的隐匿性HBV感染患者,LR-5结节可诊断为明确HCC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the diagnostic performance of contrast-enhanced (CE) US Liver Imaging Reporting and Data System (LI-RADS) version 2017 and propose a diagnostic algorithm in diagnosing hepatocellular carcinoma (HCC) in patients with occult HBV infection (OBI).

METHODS: 251 OBI patients with 251 newly diagnosed focal liver lesions were retrospectively enrolled. Each nodule was evaluated according to CEUS LI-RADS. The subgroup analyses were also performed in patients with alpha-fetoprotein (AFP) more than 20ug/L or not. Diagnostic performance of CEUS LI-RADS for diagnosing HCC was validated via sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV), respectively.

RESULTS: There were 90 HCCs (90 of 251, 35.9%), of which 2 (2.0%), 53 (53.5%), and 35 (35.4%) were classified as LR-4, LR-5, and LR-M, respectively. The sensitivity, specificity, accuracy, PPV, and NPV of CEUS LR-5 for HCC diagnosis were 58.9%, 88.8%, 78.1%, 74.6%, and 79.4%, respectively. AFP increased in 50.6% (45/89) HCCs. Using a proposed diagnostic algorithm (for OBI patients with AFP more than 20 ug/L, LR-5 nodules were diagnosed as definitely HCC), the sensitivity, specificity, accuracy, PPV, and NPV were 62.2%, 71.4%, 63.5%, 93.3%, and 22.7%, respectively. Therefore, 12.2% (30 of 246) nodules could be confirmed as HCC by CEUS without biopsy.

CONCLUSION: HCC diagnosis in patients with OBI is challenging. However, using LR-5 as a noninvasively diagnostic standard in OBI patients with AFP more than 20ug/L, HCC could be confirmed by CEUS without biopsy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Huang, Li, Hu, et al. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B. Abdom Radiol (NY). 2021. PMID: 34800160. doi:10.1007/s00261-021-03343-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。